Cells that die during inflammation send wound-healing messages 

A study by the team of Prof. Kodi Ravichandran (VIB-UGent Center for Inflammation Research) and colleagues found that pyroptosis, a form of programmed cell death traditionally thought to be purely inflammatory, also plays a crucial role in promoting healing and tissue repair. This research, published in Nature, opens new avenues for understanding how our bodies respond to injury and could lead to innovative treatments for wounds and inflammatory diseases. 

Dying cells 

About a billion cells die in our bodies every day. Most of these cells are killed by a process called apoptosis, which is a form of cellular maintenance that keeps us healthy. ​ However, under the influence of pathogens or inflammatory triggers, cells can die in a process called pyroptosis. As the name suggests (pyro means fire), pyroptosis causes significant inflammation, which helps the body clear infections, but also causes severe tissue damage. ​ 

“Cell death by pyroptosis has so far only been regarded as inflammatory and damaging in nature, but our work suggests that, besides tissue-damaging factors, pyroptosis also releases beneficial molecules that encourage wound healing, which could lead to new treatments for dealing with chronic wounds or inflammation,” says Prof. Kodi Ravichandran (VIB-UGent), one of the lead authors of this study. ​ 

Inflammation and healing 

Whenever we face an injury or infection, our body responds by mounting an immune response, which results in inflammation clearing the infection. However, when the inflammation is not resolved in a timely or controlled manner, there can be excessive tissue damage. Cells undergoing pyroptosis contribute to this inflammation by releasing inflammatory molecules. ​ 

However, new research by the team of Prof. Kodi Ravichandran and colleagues finds that these pyroptotic cells also release molecules that can encourage wound healing. ​ 

“To our surprise, using cell culture and mouse model systems, the molecules secreted by pyroptotic cells are unique. ​ These molecules induce significant gene expression changes in nearby healthy immune cells (macrophages) that promote healing and tissue repair. So, pyroptosis presses both the accelerator and the brake; on the one hand inflammatory cytokines released from pyroptotic cells cause inflammation, while metabolites and oxylipins in the secretome help the tissue to heal itself” says Dr. Parul Mehrotra, a senior and first author on the study (VIB-UGent, now at Indian Institute of Technology, Delhi). 
Dr. Parul Mehrotra, Dr. Sophia Maschalidi, and Prof. Kodi Ravichandran.

Closing wounds 

One of the key wound-healing molecules that the researchers identified is prostaglandin E2, known for its role in pain and tissue regeneration. ​ 

Dr. Sophia Maschalidi (VIB-UGent), co-first author of this work, says: “Our experiments revealed that the secreted molecules from dying cells, known as the pyroptotic secretome, can significantly boost the body's ability to repair damaged tissues even when inflammatory molecules are present.” 

This study suggests that current strategies to develop treatments by blocking pyroptosis may need to be reconsidered. While this can prevent damage, it might also inhibit the release of essential molecules that aid in tissue repair. Instead, the newly identified small molecules and lipids from the pyroptotic secretome could be harnessed to develop new therapies, offering new hope for patients suffering from chronic wounds or inflammatory diseases. 


Funding 

This research was supported by the FWO, the Special Research Fund UGent, ERC, BJC Investigator Funds, LEO Foundation EMEA Award, Priority 2030 Federal Academic Leadership Program of the Russian Federation, EMBO, Boehringer Ingelheim, and the Lawrence C. Pakula, MD IBD Innovation Fund. 

Publication 

Oxylipins and metabolites from pyroptotic cells act as promoters of tissue repair. Mehrotra, Maschalidi, et al. Nature, 2024. DOI: 10.1038/s41586-024-07585-9 


Gunnar De Winter

Gunnar De Winter

Science Communications Expert, VIB

Share

Latest stories

Website preview
Blocking lipid production in healthy lung cells can reduce lung metastasis
Leuven, 17 March 2026 - Scientists from the VIB–KU Leuven Center for Cancer Biology, in collaboration with the Francis Crick Institute, have discovered how cancer cells can exploit healthy lung cells to support metastatic tumor growth in the lungs. In two complementary studies published in Nature Cell Biology and Cancer Discovery, they show that tumors use lipids produced by lung cells as signals, and that decreasing the lipid production of lung cells can decrease metastasis. The findings point to new therapeutic strategies that target lung cell lipid production, rather than cancer cells themselves, which may also help refine patient selection for ongoing clinical trials targeting this pathway.
press.vib.be
Website preview
Researchers identify major genetic risk factor for rare form of dementia
Antwerp, 12 March 2026 - Researchers at VIB and Antwerp University have identified a major genetic risk factor for a rare form of frontotemporal dementia. The discovery, published today in Nature Genetics, provides a biological entry point for a disease subtype that has been difficult to study. It could not only help to improve diagnosis and patient stratification, but also opens up new avenues toward targeted treatments.
press.vib.be
Website preview
Protealis Announces Regulatory Approval of its First Biological Solution MagNfixTM and Launch of Five New Soybean Varieties
Ghent (Belgium), 11 March 2026 – Protealis, the European specialist in non-GMO legume seeds and seed technologies, today announces several milestones that significantly strengthen its position in a fast-growing European soybean market. The company has obtained European regulatory approval from EFCI1 (EU Fertilising Products Regulation (FPR) 2019/1009) for MagNfix™, its first biological solution, which is a proprietary soybean inoculant seed coating that is designed to support higher soybean yield and protein content. In addition, Protealis has secured the registration of five new soybean varieties across four European countries. This includes the introduction of two new maturity group (MG) 000 soybean varieties in Poland, the registration of its first maturity group 0000 ultra-early soybean variety in France, and a new soy variety registration for Belgium. In Germany, Protealis received registration for its second 00 MG soybean variety suited for the regions in southern Germany...
press.vib.be

About VIB Press

VIB is an independent research institute that translates insights in biology into impactful innovations for society. Collaborating with the five Flemish universities, it conducts research in plant biology, cancer, neuroscience, microbiology, inflammatory diseases, artificial intelligence and more. VIB connects science with entrepreneurship and stimulates the growth of the Flemish biotech ecosystem. The institute contributes to solutions for societal challenges such as new methods for diagnostics and treatments, as well as innovations for agriculture. 

Learn more at www.vib.be.

Contact

Suzanne Tassierstraat 1 9052 Zwijnaarde

+32 9 244 66 11

press@vib.be

vib.be